TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Transplant;Failure,KidneyPain, Postoperative
Interventions
DRUG

Ropivacaine Continuous Infusion Catheter

For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.

DRUG

Single Dose Liposomal Bupivicaine

TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.

Trial Locations (1)

95817

RECRUITING

University of California Davis, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER